ATE280588T1 - Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren - Google Patents
Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahrenInfo
- Publication number
- ATE280588T1 ATE280588T1 AT99939127T AT99939127T ATE280588T1 AT E280588 T1 ATE280588 T1 AT E280588T1 AT 99939127 T AT99939127 T AT 99939127T AT 99939127 T AT99939127 T AT 99939127T AT E280588 T1 ATE280588 T1 AT E280588T1
- Authority
- AT
- Austria
- Prior art keywords
- dextran
- pharmaceutical compositions
- related methods
- leptin conjugates
- leptin
- Prior art date
Links
- 229940039781 leptin Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9619498P | 1998-08-10 | 1998-08-10 | |
| US37068499A | 1999-08-09 | 1999-08-09 | |
| PCT/US1999/018129 WO2000009165A1 (en) | 1998-08-10 | 1999-08-10 | Dextran-leptin conjugates, pharmaceutical compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE280588T1 true ATE280588T1 (de) | 2004-11-15 |
Family
ID=26791397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99939127T ATE280588T1 (de) | 1998-08-10 | 1999-08-10 | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1107793B1 (de) |
| JP (1) | JP4199421B2 (de) |
| AT (1) | ATE280588T1 (de) |
| AU (1) | AU5347099A (de) |
| CA (1) | CA2337667C (de) |
| DE (1) | DE69921486T2 (de) |
| ES (1) | ES2228082T3 (de) |
| PT (1) | PT1107793E (de) |
| WO (1) | WO2000009165A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| ATE323766T1 (de) * | 1999-02-12 | 2006-05-15 | Amgen Inc | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
| GB0116860D0 (en) * | 2001-07-10 | 2001-09-05 | Univ Montfort | Gel compositions |
| WO2005094898A2 (en) * | 2004-03-23 | 2005-10-13 | Amgen Inc. | Chemically modified protein compositions and methods |
| CN101143894A (zh) * | 2007-06-22 | 2008-03-19 | 中国药科大学 | 高效抑制血管生成多肽及其物理化学修饰方法和应用 |
| JP5622720B2 (ja) | 2008-05-21 | 2014-11-12 | ニューロテスインコーポレイテッド | 神経原繊維変化に関連する進行性認知障害の治療方法 |
| US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| CA2742600A1 (en) | 2008-11-04 | 2010-05-14 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta |
| JP2014502252A (ja) | 2010-09-28 | 2014-01-30 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 作用持続時間が増した改変ポリペプチド |
| US9968575B2 (en) | 2012-09-27 | 2018-05-15 | The Children's Medical Center Corporation | Compounds for the treatment of obesity and methods of use thereof |
| HRP20190219T1 (hr) | 2013-11-26 | 2019-03-22 | The Children's Medical Center Corporation | Spojevi za tretman pretilosti i postupci za njihovu uporabu |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| PL3509624T3 (pl) | 2016-09-12 | 2024-03-25 | Amryt Pharmaceuticals Inc. | Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE259650T1 (de) * | 1995-08-17 | 2004-03-15 | Amgen Inc | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen |
| AU2670897A (en) * | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
-
1999
- 1999-08-10 JP JP2000564666A patent/JP4199421B2/ja not_active Expired - Lifetime
- 1999-08-10 WO PCT/US1999/018129 patent/WO2000009165A1/en not_active Ceased
- 1999-08-10 AT AT99939127T patent/ATE280588T1/de active
- 1999-08-10 EP EP99939127A patent/EP1107793B1/de not_active Expired - Lifetime
- 1999-08-10 DE DE69921486T patent/DE69921486T2/de not_active Expired - Lifetime
- 1999-08-10 ES ES99939127T patent/ES2228082T3/es not_active Expired - Lifetime
- 1999-08-10 PT PT99939127T patent/PT1107793E/pt unknown
- 1999-08-10 CA CA002337667A patent/CA2337667C/en not_active Expired - Lifetime
- 1999-08-10 AU AU53470/99A patent/AU5347099A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000009165A1 (en) | 2000-02-24 |
| CA2337667C (en) | 2008-04-29 |
| ES2228082T3 (es) | 2005-04-01 |
| JP4199421B2 (ja) | 2008-12-17 |
| EP1107793B1 (de) | 2004-10-27 |
| EP1107793A1 (de) | 2001-06-20 |
| DE69921486T2 (de) | 2006-02-02 |
| AU5347099A (en) | 2000-03-06 |
| DE69921486D1 (de) | 2004-12-02 |
| JP2002522512A (ja) | 2002-07-23 |
| CA2337667A1 (en) | 2000-02-24 |
| PT1107793E (pt) | 2005-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1157037T3 (da) | GCSF-konjugater | |
| ES2184149T3 (es) | Paclitaxeles 6-tio sustituidos. | |
| CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
| DK0971717T3 (da) | Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler | |
| NO20002785D0 (no) | Adamantanderivater | |
| NO20002786D0 (no) | Adamantanderivater | |
| EP1100522A4 (de) | Verabreichung aktiver wirkstoffe über die lunge | |
| ATE556706T1 (de) | Fettalkohol-arzneimittel-konjugate | |
| TR200100054T2 (tr) | Paroksetin metansülfonat | |
| ATE231872T1 (de) | Thiazolopyrimidinderivate | |
| TR199801861T2 (xx) | Farmas�tik olarak yararl� bile�imler. | |
| IL150225A0 (en) | Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof | |
| DE69921486D1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
| BR0014355A (pt) | Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva | |
| DE60113445D1 (de) | Substanzen mit verzweigten linkermolekülen | |
| EE200200281A (et) | Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks | |
| ES2132556T3 (es) | Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen. | |
| EE03996B1 (et) | Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine | |
| TR200103827T2 (tr) | Farmakolojik kompleks | |
| DE50004023D1 (de) | 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one | |
| SE9803107D0 (sv) | Novel Compunds | |
| DK1011329T3 (da) | 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler | |
| CY1111290T1 (el) | Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης | |
| SE9803277D0 (sv) | Novel compounds | |
| IT1311913B1 (it) | Impiego di 6-metilmercaptopurina riboside in composizionioftalmologiche. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1107793 Country of ref document: EP |